DoximityDOCS

Public company

Overview Company profile News

The Inference

Independent and free to read. Experts Editors's voice on AI and tech companies

contact@theinference.org

Sections

News

Company

About
The editor
Contact us
Corrections
Confidential tips

Legal

Terms of use
Privacy

Get your curated digest

After email confirmation, you will receive a daily digest of the most relevant news that matter to your portfolio

Overview Company profile News

Market snapshot

DOCS

30.40USD▲ 3.47%+1.02 today

Closed: Oct 9 6:30 PM EDT

Hover to inspect recorded prices. Click to pin a point; click again to release. Drag between two points to measure the return over that span. Use arrow keys to move, shift with an arrow key to extend a span, Home or End to jump, and Escape to clear.

Market cap: —
Open: 29.45
High: 30.50
Low: 29.17

Day figures as of Oct 9 6:30 PM EDT · previous close 29.38

Latest on Doximity

Featured · Health

$15 Billion for a Free Tool: OpenEvidence Bets Its Doctors' Reach on Hospitals and Cancer Trials

OpenEvidence confirmed $250 million at a $15 billion valuation, a quarter under the $20 billion it had reportedly shopped, while three health systems switched the free tool on and its first cancer candidate heads into trials before year-end. Doctors still pay nothing; the valuation rests on what their traffic can be sold as.

October 3, 2026 · 3 min read

Health
OpenEvidence Gives Doctors AI for Free. The Court Fight Shows What Free Costs.
Penn Medicine is handing OpenEvidence 10,000 clinicians for nothing, and a quiet round valued the ad-funded tool at $15 billion, below the $20 billion it reportedly sought. Doximity's motion to dismiss reads as the same fight in another venue: who actually pays for clinical AI.
September 29, 2026 · 3 min read

Market snapshot

Latest on Doximity

$15 Billion for a Free Tool: OpenEvidence Bets Its Doctors' Reach on Hospitals and Cancer Trials

OpenEvidence Gives Doctors AI for Free. The Court Fight Shows What Free Costs.